Product Details

Teva-Dutasteride

Dutasteride
0.5 mg
Capsule

DIN/PIN/NPN

02408287

Manufacturer

Teva Canada Limited

Formulary Listing Date

2014-09-25

Unit Price

0.2565

Amount MOH Pays

0.2565

Coverage Status

Limited Use Product Chronic-Use Medication

ODB Formulary Therapeutic Classification

92:00:00 Unclassified Therapeutic Agents

Therapeutic Note

NO

ATC Code

G04CB02

Interchangeable Products

DIN/ PIN/ NPN	Brand name	Unit Price	Amount MOH pays
02490587	Priva-Dutasteride	0.2565	0.2565
02408287	Teva-Dutasteride	0.2565	0.2565
02424444	Sandoz Dutasteride	0.2565	0.2565
02393220	PMS-Dutasteride	0.2565	0.2565
02428873	Mint-Dutasteride	0.2565	0.2565
02416298	Med-Dutasteride	0.2565	0.2565
02484870	Jamp Dutasteride	0.2565	0.2565
02443058	Dutasteride	0.2565	0.2565
02429012	Dutasteride	0.2565	0.2565
02247813	Avodart	2.1070	0.2565
02469308	Auro-Dutasteride	0.2565	0.2565
02404206	Apo-Dutasteride	0.2565	0.2565

LU Clinical Criteria

LU Code	Auth. Period	Clinical Criteria
384	Indefinite	For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia. *Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains: 1. feeling of incomplete emptying of the bladder after voiding 2. needing to urinate again less than 2 hours after previous void 3. stopping and starting urine several times while voiding 4. difficulty postponing urination 5. weak urinary stream 6. pushing or straining to begin voiding 7. the need to get up to void at least 3 times in the night.
385	Indefinite	For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker. *Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains: 1. feeling of incomplete emptying of the bladder after voiding 2. needing to urinate again less than 2 hours after previous void 3. stopping and starting urine several times while voiding 4. difficulty postponing urination 5. weak urinary stream 6. pushing or straining to begin voiding 7. the need to get up to void at least 3 times in the night.

EAP Criteria

NO

Product Monograph